Skip to main navigation Skip to search Skip to main content

Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia in the ICU A Multicenter, Randomized Controlled Trial

  • Xiaojing Wu
  • , Ting Sun
  • , Hangyong He
  • , Lihua Xing
  • , Zhenshun Cheng
  • , Shuang Geng
  • , Dexiang Xu
  • , Hong Luo
  • , Cheng Chen
  • , Mingyan Jiang
  • , Guopeng Hou
  • , Tianshu Zhai
  • , Ying Cai
  • , Yijie Liu
  • , Junlu Li
  • , Lan Ni
  • , Xueying Li
  • , Binbin Qu
  • , Cheng Lei
  • , Yang Wang
  • Zi Gu, Peng Zhang, Xu Huang, Min Li, Jingen Xia, Lian He, Qingyuan Zhan*
*Corresponding author for this work
  • China Japan Friendship Hosp
  • Chinese Acad Med Sci
  • Nanchang Univ
  • Capital Med Univ
  • Binzhou Med Univ Hosp
  • Zhengzhou Univ
  • Huazhong Univ Sci & Technol
  • Qingdao Univ
  • Cent South Univ
  • Soochow Univ
  • Mianyang Cent Hosp
  • Third Peoples Hosp Datong
  • Peking Union Med Coll & Chinese Acad Med Sci
  • Second Peoples Hosp Guiyang

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

BACKGROUND: Metagenomic next-generation sequencing (mNGS) was previously established as a method that can increase the pathogen identification rate in patients with severe community-acquired pneumonia (SCAP). RESEARCH QUESTION: What is the impact on clinical outcomes of mNGS of BAL fluid (BALF) in patients with SCAP in the ICU? STUDY DESIGN AND METHODS: A multicenter randomized controlled open-label clinical trial was conducted in 10 ICUs. Patients were randomized in a 1:1 ratio to undergo BALF assessment with conventional microbiological tests (CMTs) only (ie, the CMT group) or BALF assessment with both mNGS and CMTs (ie, the mNGS group). The primary outcome was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a six-category ordinal scale or discharge from the ICU, whichever occurred first. RESULTS: A total of 349 patients were randomized to treatment between January 1, 2021, and November 18, 2022; 170 were assigned to the CMT group and 179 to the mNGS group. In the intention-to-treat analysis, the time to clinical improvement was better in the mNGS group than in the CMT group (10 days vs 13 days; difference, -2.0 days; 95% CI, -3.0 to 0.0 days). Similar results were obtained in the per-protocol analysis. The proportion of patients with clinical improvement within 14 days was significantly higher in the mNGS group (62.0%) than in the CMT group (46.5%). There was no significant difference in other secondary outcomes. INTERPRETATION: We found that compared with the use of CMTs alone, mNGS combined with CMTs reduced the time to clinical improvement for patients with SCAP.
Original languageEnglish
Pages (from-to)362-373
Number of pages12
JournalChest
Volume167
Issue number2
DOIs
StatePublished - Feb 2025

Funding

This study was supported by the National High-Level Hospital Clinical Research Funding [2022-NHLHCRF-LX-01-01] , the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [2022-I2M-JB-016] , National High Level Hospital Clinical Research Funding-Elite Medical Professionals Project of China-Japan Friendship Hospital [ZRJY2023-GG20] , and the Key Research and Development Program of JingXi province [20232BBG7002] . The Vision Medical Co. Ltd. (China) provided funding support and mNGS test for free.

Keywords

  • clinical outcomes
  • ICUs
  • metagenomic next-generation sequencing
  • severe community-acquired pneumonia

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia in the ICU A Multicenter, Randomized Controlled Trial'. Together they form a unique fingerprint.

Cite this